TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Docetaxel/Gemcitabine Followed by Chemo-radiotherapy (Chemo-RT), With or Without Consolidation Chemotherapy, in IIIA/IIIB Non Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histologically or cytologically confirmed, unresectable locally advanced (stage IIIA/IIIB) NSCLC~* no previous therapy for NSCLC is allowed~* age \>18 years~* bidimensionally measurable disease~* performance status (WHO) 0-2~* absence of pleural effusion~* adequate liver (serum bilirubin \< 1.5 times the upper normal limit (UNL); AST and ALT \< 2.5 times the UNL in the absence of demonstrable liver metastases, or \< 5 times the UNL in the presence of liver metastases); adequate renal function (serum creatinine \< 1.5 times the UNL); and bone marrow (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L) function~* life expectancy of more than 3 months~* written informed consent~Exclusion Criteria:~* active infection~* history of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias)~* malnutrition (loss of ≥ 20% of the original body weight)~* performance status: 3-4~* sensor or motor neuropathy \> grade I~* second primary malignancy, except for non-melanoma skin cancer~* psychiatric illness or social situation that would preclude study compliance~* pregnant or lactating women

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): DG -\> RT
- 2 (Type: EXPERIMENTAL): DG -\> RT -\> DCarbo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females older than 18 years of age~* Is clinically indicated for MRCP of the pancreas based on prior imaging features suggestive or suspicious of IPMN (eg. Cystic lesion in the pancreas along the duct, ductal dilatation)~* Scheduled for MRCP and therapeutic or diagnostic ERCP or surgery for the IPMN~* Has been fully informed and has personally signed and dated the Written Informed Consent and Health Insurance Portability Accountability Act (HIPAA) provisions~* Is a male, or is a female not of childbearing potential, or is a female of childbearing potential who is using effective contraception and has a negative serum pregnancy test on the same day, but prior to, study drug administration~* Is able and willing to complete all study procedures specified in the protocol~Exclusion Criteria:~* Presence of a pancreatic stent~* History of any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease which, in the opinion of the investigator, precludes study participation~* History of sensitivity to any of the ingredients in the study drug~* Pregnancy~* Any contraindication to MRI procedure, including but not limited to implanted metal devices (e.g., pacemaker, aneurysm clips, cochlear implants)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Drug + MR with MRCP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Balloon Kyphoplasty in Traumatic Vertebral Fractures Needing Surgical Fixation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Preliminary clinical examination (the anaesthesist must have provided his approval for the surgical procedure)~* Patient must have signed the consent form~* Male or female patient aged 18 or over~* One or two traumatic vertebral fractures located between T11 and L5 and type A3.2, A3.3, B1 or C1 in the MAGERL classification, and with a regional kyphotic angle \> 15° and treated by osteosynthesis through a posterior surgical approach with or without spinal decompression~* Fracture with or without neurological difficulties~* Non tumoral origin: Confirmed by biopsy at the same time of the Balloon Kyphoplasty procedure.~Exclusion Criteria:~* Non- traumatic, malignant or osteoporotic vertebral fractures~* History of surgical or percutaneous spine treatment except simple discectomy at a single or multiple vertebral levels with no residual pain.~* Known allergy to a contrast media or to one of the cement components used for kyphoplasty.~* More than two recent vertebral fractures~* Current infection~* Impossibility to perform the percutaneous approach of the vertebra to treat.~* Reduction by more than 50% of the anteroposterior width of the bony spinal canal due to the vertebral fracture to treat.~* Vertebral fracture with loss of 90%or more of the vertebral body height~* Patient presenting a non correctable spontaneous or therapeutic coagulation disorder.~* Evolutive cardiac disease nonreactive to medical treatment~* Non compliant patient: Impossibility to participate to the study and to be followed up for 1 year.~* Pregnant or breast feeding women~* Patient not affiliated to social security

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Balloon kyphoplasty

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of pediatric/adolescent solid tumor (including neuroblastoma, rhabdomyosarcoma, Ewing's/PNET, osteosarcoma, brain tumors, desmoplastic small round cell tumor (DSRT) and other tumors that are 8H9-positive) confirmed by the MSKCC Department of Pathology.~* Patient must have either recurrent disease or have \<20% chance of long term disease-free survival.~* Patient must be at least 1 year old. Age can range from 1-50 years of age.~* Patients should have measurable or evaluable disease. For tumor types that are known to be 8H9-positive, patients can be imaged after the diagnosis is made, prior to definitive surgery or surgery to confirm tumor recurrence.~* Tumor tissue is or will be available for 8H9 immunostaining. For patients with tumor-types known to be 8H9-positive, surgical samples obtained after 131I- 8H9 imaging will be immunostained to confirm 8H9-reactivity. These tumor types include: neuroblastoma, rhabdomyosarcoma, osteosarcoma, DSRT, Ewing's Sarcoma/PNET), brain tumors (glioblastoma multiforme, mixed glioma, astrocytoma, ependymoma, medulloblastoma, schwannoma., meningioma).~* If frozen tumor tissue is unavailable, and if bone marrow involvement is demonstrated by histology, 8H9 immunostaining by immunofluorescence will be carried out on patient's bone marrow. In this case, patients will be eligible for study if bone marrow 8H9 immunostaining is positive.~Exclusion Criteria:~* Severe major organ toxicity. Specifically, renal, cardiac, hepatic, pulmonary, gastrointestinal, and neurologic system toxicity should all be less than grade 2. Patients with stable neurological deficits (because of their brain tumor) are not excluded. Patients with \<= 3 hearing loss are not excluded.~* Clinically apparent infections.~* History of allergy to iodine or mouse proteins.~* Patients previously treated with mouse monoclonal antibodies are not eligible unless they have no circulating HAMA.~* Pregnant women are excluded for fear of danger to the fetus. Therefore negative pregnancy test is required for all women of child-bearing age, and appropriate contraception is used during the study period.~* Patient's own tumor is negative by 8H9 immunostaining.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 131I-8H9 and 8H9 (Type: EXPERIMENTAL): This is an open-label single arm study of 131 I-8H9. injected intravenously at 10mCi/1.73m\^2 dose \[intended specific activity of '20mCi/mg protein\] preceded by administration of 50mg/1.73m2 of unlabeled -8H9.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Radical prostatectomy for prostate cancer within last 2 months.~* Post-operative Kattan nomogram predicts \>25% risk of PSA relapse by 5 years.~* 6-week post-operative serum PSA\<0.2ng/mL.~* Low levels of circulating prostate cancer cells in the blood, detected by PCR amplification of PSA mRNA 6 weeks post-prostatectomy.~Exclusion Criteria:~* Pre-operative serum PSA level \>20ng/ml.~* Clinical evidence of metastases by 6-week post-operative visit.~* Prior treatment with either ADT or bisphosphonate therapy.~* Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.~* Recent (within 6 weeks) or planned dental or jaw surgery (e.g.extraction, implants)~Other protocol defined inclusion / exclusion criteria may apply.

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zoledronic Acid (Type: EXPERIMENTAL): None
- Docetaxel (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Evaluation Among Patients Infected by HIV 1 in Virological Failure Owing to Lack of Compliance, of the Benefit in Terms of Compliance of an Optimised Antiretroviral Treatment With Enfuvirtide (Fuzeon) Associated With Two Active Molecules

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* virological failure, more than 18 years, prouved lack of compliance, with no sub-optimal treatment, in ambulatory status.~Exclusion Criteria:~* hospitalization,HIV2 infection,pregnancy,preliminary treatment with enfuvirtide,chimiotherapy , opportunistic infection in progress

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- enfuvirtide (Type: None): all patients would received enfuvirtide and and optimised background

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mifepristone Versus Misoprostol for Cervical Preparation Prior to Surgical Abortion Between 11 to 15 Weeks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater or equal to 18 years~* Fluency in English or Spanish~* Intrauterine pregnancy between 11 0/7 and 15 0/7 on the day of the abortion procedure~* Desire for pregnancy termination~* Ability to return for abortion procedure 24-48 hours after the preoperative visit~Exclusion Criteria:~* Allergy or contraindication to study agents~* Requirement of general anesthesia to perform the abortion~* Diagnosis of missed abortion, spontaneous abortion, incomplete abortion, or threatened abortion at time of initial preoperative evaluation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mifepristone (Type: EXPERIMENTAL): Subjects will receive 200 mg of capsulized mifepristone orally for the purpose of cervical preparation before surgical abortion
- Misoprostol (Type: ACTIVE_COMPARATOR): Subjects will receive 400 mcg of buccal misoprostol for the purposes of cervical preparation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fully Automated Scan Technique Optimisation of Scan Timing in Chest CT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients referred for standard chest CT~* Patients older than 18 years and competent to give informed consent~Exclusion Criteria:~* Hemodynamic instability;~* Pregnancy;~* Renal insufficiency (defined as Glomerular Filtration Rate (GFR) \< 30 mL/min (Odin protocol 004720));~* Iodine allergy;~* Age \<18 years;~* Absence of informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FAST software (Type: ACTIVE_COMPARATOR): Patient referred for chest CT and scanned with delay based on bolus tracking with FAST software. intervention: FAST START Software delay
- Control (Type: ACTIVE_COMPARATOR): Patient referred for chest CT and scanned with delay based on bolus tracking without FAST software. Intervention: Manual bolus tracking delay

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Ferric Carboxymaltose (Ferinject) in Patients Undergoing Orthopaedic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age \>= 18 years~* Patients scheduled to undergo hip or knee replacement~* 8 g/dl \< Hb \< 13 g/dl for men and 8 g/dl \< Hb \< 12 g/dl for women at screening (3-4 weeks prior to surgery)~* anemia~* signed written informed consent~Exclusion Criteria:~* immunosuppressive or myelosuppressive therapy~* history of thromboembolic events~* a concurrent medical condition(s) that would prevent compliance or participation or jeopardize the health of the patient~* hypersensitivity to any component of the formulation~* transfusion within 1 month prior to study inclusion~* liver values 3 times higher than normal~* active severe infection/inflammation~* renal insufficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NaCl 0.9% (Type: PLACEBO_COMPARATOR): None
- Ferinject (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Putting Life in Years (PLINY): Telephone Friendship Groups Research Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 75 years or over~* Good cognitive function, defined as Six Cognitive Impairment Test Brooke P, Bullock R, 1999) score of 7 or under;~* Living independently (including those who are co-resident with others) or in sheltered/ extra care housing;~* Able to understand and converse in English.~Exclusion Criteria:~* Aged 74 years or younger~* 6CIT score of 8 or more~* In residential/ nursing care homes~* Unable to understand and converse in English~* Unable to converse on the telephone with assertive technology 6. Already receiving a telephone intervention

- Gender: ALL
- Minimum Age: 75 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Telephone friendship groups (Type: ACTIVE_COMPARATOR): Participants allocated to telephone friendship groups will take part in 12 weekly group telephone discussions. The participant will be called, by a trained Age UK Sheffield volunteer, in their own home. The group discussions will take place for about an hour each week and involve between 6-8 participants. Participants will be introduced to weekly group calls by the volunteer who will call each participant individually for around 20 minutes each week for up to six weeks before the group is established.~The group may have a particular focus or talk about different topics each week. The individual participants are joined together through a teleconferencing system (provided by Community Network).
- Usual health and social care (Type: NO_INTERVENTION): Participants allocated to the control arm will not receive any research intervention. However, they will participate in the research by completing questionnaires about their health and wellbeing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Ravulizumab in ALS Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. A diagnosis of sporadic or familial ALS, defined by the El Escorial criteria (possible, laboratory-supported probable, probable, or definite ALS).~2. ALS onset ≤ 36 months from Screening.~3. Documented meningococcal vaccination not more than 3 years prior to, or at the time of, initiating study treatment.~4. Upright slow vital capacity ≥ 65% predicted at Screening.~5. If on riluzole, participant must be on a stable dose for 30 days; if on edaravone, participant must be on a stable dose for 60 days (2 cycles).~6. Body weight ≥ 40 kilograms at Screening.~7. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.~Key Exclusion Criteria:~1. History of Neisseria meningitidis infection.~2. Human immunodeficiency virus (HIV) infection (evidenced by HIV 1 or HIV 2 antibody titer).~3. Dependence on invasive or non-invasive mechanical ventilation.~4. Previously or currently treated with a complement inhibitor.~5. Exposure to an investigational drug or device within 30 days of Screening or 5 half lives of the study drug, whichever is greater.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ravulizumab (Type: EXPERIMENTAL): Participants will receive ravulizumab for the duration of the study.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo during the 50-week Randomized Controlled Period of the study, after which they will enter the Open-label Extension Period of the study and switch to receive ravulizumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Acute Kidney Injury in Patients With NSTEMI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Informed Consent as documented by a signature and date of the patient~2. Age 18-85 years~3. Acute NSTEMI as anticipated to be type 1 (expert opinion by the cardiologist before coronary angiography) and scheduled for urgent coronary angiography~4. Documented kidney disease existing for ≥3 months OR Two estimated glomerular filtration rate (eGFR) measurements of \<60ml/min/1.73m2 as calculated by the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) study equation and at least 6 hours apart OR eGFR of \<50 mL/min//1.73m2 as calculated by using the CKD-EPI study equation at presentation~5. At least one of the following risk factors for AKI: diabetes mellitus, age \>60 years, established cardiovascular disease, heart failure with reduced ejection fraction, anemia~Exclusion Criteria:~1. Contraindications to the class of drugs under study (C1 esterase inhibitors), e.g. known hypersensitivity or allergy to class of drugs or the IMP~2. History or suspicion of allergy to rabbits~3. Women who are pregnant or breast feeding~4. ST elevation myocardial infarction or unstable angina~5. Cardiogenic shock requiring mechanical support~6. Non-cardiac comorbidity with expected survival \<6 months~7. Acute urinary tract infection (e.g. cystitis, pyelonephritis).~8. Liver cirrhosis (any Child-Pugh score)~9. Dialysis or eGFR \<20 and \>59mL/min/1.73 m2 at baseline (d0)~10. Incapacity or inability to provide informed consent~11. Participation in another study with investigational drug within 30 days preceding, and during the present study~12. Previous enrolment into the current study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Conestat alfa 50 U/kg - Placebo (Type: PLACEBO_COMPARATOR): 50 U/kg conestat alfa pre-angiography and placebo 3 hours after the first dose
- Conestat alfa 50 U/kg - Conestat alfa 50 U/kg (Type: ACTIVE_COMPARATOR): 50 U/kg conestat alfa pre-angiography and 3 hours after the first dose
- Conestat alfa 100 U/kg - Conestat alfa 50 U/kg (Type: ACTIVE_COMPARATOR): 100 U/kg conestat alfa pre-angiography and 50 U/kg conestat alfa 3 hours after the first dose
- Placebo - Placebo (Type: PLACEBO_COMPARATOR): Placebo pre-angiography and 3 hours after the first dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues